Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Neutral Smith (DS) (SMDS) by UBS
- Hold JD Sports Fashion (JD.) by Harvey Jones in The Motley Fool
- Strong Buy Taylor Wimpey (TW.) by Harvey Jones in The Motley Fool
- Outperform Diageo (DGE) by ODDO BHF
- Hold WH Smith (SMWH) by Deutsche Bank
- Hold Burberry Group (BRBY) by Deutsche Bank
- Hold Just Group (JUST) by Deutsche Bank
- Buy 3i Group (III) by Deutsche Bank
- Buy TT Electronics (TTG) by Deutsche Bank
- Buy Spirax Group (SPX) by HSBC
- Buy Aviva (AV.) by HSBC
- Buy Flutter Entertainment (DI) (FLTR) by Berenberg
- Neutral Burberry Group (BRBY) by Goldman Sachs
- Neutral Croda International (CRDA) by Goldman Sachs
- Buy Direct Line Insurance Group (DLG) by Goldman Sachs
- Buy B&M European Value Retail S.A. (DI) (BME) by Goldman Sachs
- Overweight Travis Perkins (TPK) by Barclays
- Underweight Treatt (TET) by Barclays
- Equal Weight Whitbread (WTB) by Barclays
- Underweight Boohoo Group (BOO) by Barclays
Belluscura (BELL) Share Price
Health Care Sector
NOTE: This is based on 3 open tips for Belluscura (BELL)
| Latest Bid : 10.00p | Latest Ask : 10.50p |
| High Today : 10.25p | Low Today : 10.05p |
| This Years High : 25.50p | This Years Low : 7.25p |
| Volume : 580 | MKT Cap : £17.64M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
Belluscura (BELL) Overview
Belluscura focuses on novel oxygen-based treatment platforms that can be adapted and applied in a wide range of markets beyond those traditionally applicable to a single product or product line. Its range of portable products will be lighter / more adaptable / have higher O₂ capacity than existing oxygen enrichment products. Whilst potentially useful for recovering COVID patients, it has a wide range of use for sufferers of pneumonia / COPD (i.e. asthma/ emphysema /chronic bronchitis) and other respiratory illnesses.Belluscura (BELL) Latest Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Sell | Tom Winnifrith | Premium Only | 2024-01-02 08:10:00 02/01/2024 | 52.27% |
| Buy | Joanne Hart | Premium Only | 2022-11-12 21:50:00 12/11/2022 | -83.33% |
| Buy | Stuart Blair | Premium Only | 2021-08-02 08:55:00 02/08/2021 | -83.33% |
Belluscura (BELL) Active Short Positions
| Fund Manager | Position | Date | ||
|---|---|---|---|---|
| No active short positions | ||||
| Latest Bid : 10.00p | Latest Ask : 10.50p |
| High Today : 10.25p | Low Today : 10.05p |
| This Years High : 25.50p | This Years Low : 7.25p |
| Volume : 580 | MKT Cap : £17.64M |
Belluscura Overview
Belluscura focuses on novel oxygen-based treatment platforms that can be adapted and applied in a wide range of markets beyond those traditionally applicable to a single product or product line. Its range of portable products will be lighter / more adaptable / have higher O₂ capacity than existing oxygen enrichment products. Whilst potentially useful for recovering COVID patients, it has a wide range of use for sufferers of pneumonia / COPD (i.e. asthma/ emphysema /chronic bronchitis) and other respiratory illnesses.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.
Latest Belluscura Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Sell | Tom Winnifrith | Premium Only | 2024-01-02 08:10:00 02/01/2024 | 52.27% |
| Buy | Joanne Hart | Premium Only | 2022-11-12 21:50:00 12/11/2022 | -83.33% |
| Buy | Stuart Blair | Premium Only | 2021-08-02 08:55:00 02/08/2021 | -83.33% |